During the past decade, Frederiksberg Hjerteklinik conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Frederiksberg Hjerteklinik" are "Atherosclerotic Cardiovascular Disease" (1 trials), "Atrial Fibrillation" (1 trials), "Atrial Flutter" (1 trials), "Cardiovascular Diseases" (1 trials) and "Dyslipidemic" (1 trials). Many other conditions were trialed in "Frederiksberg Hjerteklinik" in a lesser frequency.

Most popular intervention types in "Frederiksberg Hjerteklinik" are "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apixaban Oral Tablet" (1 trials), "Dabigatran Etexilate Oral Capsule" (1 trials), "Edoxaban Oral Tablet" (1 trials), "Non-interventional" (1 trials) and "Rivaroxaban Oral Tablet" (1 trials). Other intervention names were less common.

The vast majority of trials in "Frederiksberg Hjerteklinik" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Frederiksberg Hjerteklinik". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Frederiksberg Hjerteklinik, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Frederiksberg Hjerteklinik, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".